Trails Edge Capital Partners Acquires 6% Stake in OnKure Therapeutics

On April 7, 2026, Trails Edge Capital Partners, LP, along with Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai, filed a Schedule 13G reporting a new 6.0% stake in OnKure Therapeutics, Inc. (OKUR). The reporting group beneficially owns 2,409,638 shares of Class A Common Stock. This acquisition was triggered by the Issuer's private placement on March 31, 2026. Trails Edge Biotechnology holds the shares directly, while Trails Edge Capital serves as the investment manager and Mr. Yehudai acts as the Chief Investment Officer, exercising voting and investment discretion. The ownership percentage is based on approximately 40,387,201 shares outstanding following the private placement. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This represents a significant new position for the investment group in the biotechnology firm.